Connbey's first three-quarter results exceeded last year's full-year stake in the company increased to 4.38 percent

On the evening of October 28th, Connbey released its third-quarter report: The Company's operating income for the first three quarters of this year was 5.394 billion yuan, up 42.57% YoY; Compared with 2017 operating income of RMB5,294 million and net profit of RMB711 million, Conebey's operating income and net profit for the first three quarters of 2018 exceeded that of the whole of last year.
it is understood that Kang Enbei deepened the promotion of large-brand large-variety projects, into the large-brand large-variety project of the brand series of products in the first three quarters of cumulative sales revenue of 3.941 billion yuan, an increase of 52.25% year-on-year, of which "Connbey" brand enteritis Ning series of products, "Golden Flute" brand compound fishy herb compound, "Golden Kang Speed Force" brand acetylcysteine foam tablets, "Connbey" brand 37 drugs and wine sales revenue reached 613 million yuan, 2 RMB60 million, RMB127 million and RMB44.65 million, up 39.87%, 143.11%, 47.12% and 131.92% YoY, respectively "Front Kang" brand Ploan and Tansorosin and other products, "cherish Ming" brand eye drops and eye health products, "Connbey" brand musk heart drops and other brands and product sales revenue have increased by about 30%. At the same time, the "T-shirt" brand Dansan Kawakubo injection through continuous unremitting efforts to develop and expand the grass-roots, private hospitals and other markets, sales volume increased by 16.65 percent year-on-year, sales revenue by excluding the "two-vote system" price of the comparable caliber increased by 13.26 percent.
For The first three quarters of this year to achieve a substantial increase in revenue and stable growth in net profit, the company's chairman Hu Jiqiang said, mainly due to the promotion and implementation of large-brand large-variety projects, at the same time, launched in February this year, science and technology innovation-driven development projects, both to enhance the competitiveness of the company's existing products, but also for the company's future business development laid the foundation.
In February this year, Connbe launched the "Science and Technology Innovation Driven Development Project", which includes three sub-projects, namely generics consistency evaluation, secondary development of large varieties, major scientific and technological innovation planning, based on reality, future-oriented, both to enhance the competitiveness of the company's existing products, but also actively seek future business development layout. At present, positive progress has been made in the promotion of the project. First of all, the company accelerated the layout of the biopharmace idly by investing in Jia and Biopharmaceity Co., Ltd., becoming its second largest shareholder and largest shareholder in the industry. Kang Enbei has also announced plans to invest in Shanghai Pudong New Area to set up a subsidiary company in Hong Kong, in order to promote Jia and Biopharmaceus Co., Ltd. equity structure adjustment, accelerate the issuance and listing of shares in the overseas recognized qualified international securities market. At the same time, included in the company's plan of generic drug varieties consistency evaluation work is being carried out in an orderly manner, Connbe holding subsidiary Jinhua Kang Enbei's Amosilin capsule through generic drug consistency evaluation, Hangzhou Cornbei's hydrochloric acid Tansorosin slow release capsules are being declared in the CDE review, other varieties work is also in a hurry to actively promote.
At present, under the influence of multiple factors, the domestic stock market has been a big impact, many high-performing listed companies have fallen to low prices, Kang Enbei since last year's operating results since the listing of the best growth since 2004, but the valuation level has fallen to the lowest level in nearly 15 years of listing, a serious departure from its due value. In the face of the cold snap in the market, In September, Connbey launched a share repurchase program with a total share repurchase amount of not more than 320 million yuan and a repurchase price of no more than 8 yuan per share, and some directors, supervisors and senior managers also increased their holdings of Conebey shares against the trend, and some employees also actively purchased Conebey shares, reflecting Connbey's practical actions to safeguard corporate value, safeguard investors' interests, express and convey firm confidence in China's economic development and the company's future prospects.
reporter also noted that as of September 30, China Securities and Finance Co., Ltd. held 117 million shares, the number of shares accounted for 4.38% of the total share capital, fully reflects the mainstream investment institutions on the value of The Connbey investment recognition. (China Securities News - China Securities News)